|
IL280000D0
|
|
Tumor reduction formulations and methods of use thereof
|
|
WO2021076723A1
|
|
Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
|
|
US10905698B1
|
|
Methods of treating SARS-COV-2 infections
|
|
WO2020232227A1
|
|
Compositions and methods for treating cancer
|
|
WO2020197875A1
|
|
D-metyrosine compositions and methods for preparing same
|
|
AU2019309757A1
|
|
Tumor reduction formulations and methods of use thereof
|
|
US2019275117A1
|
|
Pharmaceutical compositions and methods
|
|
US2020405680A1
|
|
Transdermal formulations
|
|
CA3045110A1
|
|
Tyrosine derivatives and compositions comprising them
|
|
MX2019005450A
|
|
Pharmaceutical compositions and methods for the treatment of cancer.
|
|
EP3458071A1
|
|
Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
|
|
US2019091252A1
|
|
Pharmaceutical compositions for the treatment of cancer
|
|
US2017080093A1
|
|
Tyrosine Derivatives And Compositions Comprising Them
|
|
US2017056371A1
|
|
Pharmaceutical compositions and methods
|
|
US2015112116A1
|
|
Tyrosine derivatives and compositions comprising them
|
|
US2015110735A1
|
|
High-speed centrifugal mixing devices and methods of use
|
|
KR20140135704A
|
|
Pharmaceutical compositions and methods
|
